NasdaqGS:RPRXPharmaceuticals
Will Royalty Pharma's (RPRX) Dividend Hike and Guidance Reset Change Its Efficiency and Growth Narrative
Royalty Pharma, which acquires rights to portions of biopharmaceutical sales instead of conducting its own research, recently raised its dividend to US$0.235 payable in March 2026 and issued higher guidance ahead of its fourth quarter and full-year 2025 results scheduled for February 11, 2026.
This comes after two years of flat sales and a 4.4 percentage point drop in adjusted operating margin over five years, highlighting the tension between investor optimism and questions about how the...